Abstract

The details of the pediatric immune system that supports induction of antibodies capable of neutralizing geographically-diverse or heterologous HIV-1 is currently unclear. Here we explore the pediatric immune environment in neonatal macaque undergoing Simian-HIV infection. Simian-HIV infection of 11 pairs of therapy-naive dams and infant rhesus macaques for 24 months results in heterologous HIV-1 neutralizing antibodies in 64% of young macaques compared to 18% of adult macaques. Heterologous HIV-1 neutralizing antibodies emerge by 12 months post-infection in young macaques, in association with lower expression of immunosuppressive genes, fewer germinal center CD4 + T regulatory cells, and a lower ratio of CD4 + T follicular regulatory to helper cells. Antibodies from peripheral blood B cells in two young macaques following SHIV infection neutralize 13% of 119 heterologous HIV-1 strains and map to regions of canonical broadly neutralizing antibody epitopes on the envelope surface protein. Here we show that pediatric immunity to SHIV infection in a macaque model may inform vaccine strategies to induce effective HIV-1 neutralizing antibodies in infants and children prior to viral exposure.

The specifics of the pediatric immune response that gives rise to antibodies capable of neutralising diverse HIV-1 strains is not fully understood. Here the authors characterise the immune environment of Simian-HIV infected paediatric macaques and link to antibody neutralisation induction.

Details

Title
Neonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus Macaques
Author
Holmes, Sommer 1   VIAFID ORCID Logo  ; Li, Hui 2 ; Shen, Xiaoying 3   VIAFID ORCID Logo  ; Martin, Mitchell 1 ; Tuck, Ryan 1   VIAFID ORCID Logo  ; Chen, Yue 1 ; Giorgi, Elena E. 4 ; Kirshner, Hélène Fradin 1 ; Berry, Madison 1 ; Van Italie, Elizabeth 1 ; Venkatayogi, Sravani 1 ; Martin Beem, Joshua S. 1 ; Edwards, Robert J. 1   VIAFID ORCID Logo  ; Mansouri, Katayoun 1 ; Singh, Ajay 2 ; Kuykendall, Cindy 1 ; Gurley, Thaddeus 1 ; Anthony Moody, M. 5 ; DeNayer, Nicole 1 ; Demarco, Todd 1 ; Denny, Thomas N. 6 ; Wang, Yunfei 1   VIAFID ORCID Logo  ; Evangelous, Tyler D. 1 ; Clinton, John T. 1 ; Hora, Bhavna 1 ; Wagh, Kshitij 7   VIAFID ORCID Logo  ; Seaman, Michael S. 8 ; Saunders, Kevin O. 9   VIAFID ORCID Logo  ; Solomotis, Nicholas 10 ; Misamore, Johnathan 10 ; Lewis, Mark G. 10   VIAFID ORCID Logo  ; Wiehe, Kevin 6 ; Montefiori, David C. 11   VIAFID ORCID Logo  ; Shaw, George M. 2 ; Williams, Wilton B. 12   VIAFID ORCID Logo 

 Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961) 
 University of Pennsylvania, Departments of Medicine and Microbiology, Perelman School of Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
 Duke University School of Medicine, Department of Surgery, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961) 
 Fred Hutchinson Cancer Center, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622) 
 Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Integrative Immunobiology, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Pediatrics, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961) 
 Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Medicine, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961) 
 Los Alamos National Laboratory, Los Alamos, USA (GRID:grid.148313.c) (ISNI:0000 0004 0428 3079) 
 Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Surgery, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Integrative Immunobiology, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Molecular Genetics and Microbiology, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961) 
10  BIOQUAL Inc., Rockville, USA (GRID:grid.282501.c) (ISNI:0000 0000 8739 6829) 
11  Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Surgery, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961) 
12  Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Surgery, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Integrative Immunobiology, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961) 
Pages
10302
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3133604051
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.